# Syncom Healthcare share price (Syncom Healthcare Ltd, NSE: SYNCOM) > Syncom Healthcare share price: ₹4.20 at the NSE close on 28 June 2021, the latest close in our records; up 50.0% in the year to that date. Syncom Healthcare (NSE: SYNCOM) is worth ₹16.8 crore and has closed between ₹1.15 and ₹5.35 over the past 52 weeks. > Syncom Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. SYNCOM · Pharma - Formulators · data as of 28 June 2021. Page: https://www.sectoralpha.in/stocks/syncom-healthcare-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Price: ₹4.20 (+50.0% in a year) - Revenue (Jun 2021): ₹0.3 Cr (+9.4% on a year ago) - Profit (Jun 2021), incl. one-off: −₹1.1 Cr (one-off item, see below) - Operating margin: −225.7% (+86.8 points on a year ago) - ROCE: −20%, FY23 - Profit that came in as cash: 760%, last 2 years The main question: promoters moved −24.9 percentage points over 8 quarters while the business went the other way. ## What is the Syncom Healthcare share price? Syncom Healthcare Ltd's share price was ₹4.20 at the close on 28 June 2021. It has been rising for 28 weeks. That is 51.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1 and ₹5, and at that close it sat 73% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 8 weeks in a row. Over the last 5.2 years the share price moved −38% while the NIFTY 500 moved +110%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What are Syncom Healthcare's latest quarterly results? For April to June 2021 (the quarter ended 30 June 2021), Syncom Healthcare reported revenue of ₹0.35 crore, up 9.4% from ₹0.32 crore a year earlier, and a loss of ₹1.11 crore. ### Syncom Healthcare results: April to June 2021 against a year earlier | Measure | April to June 2021 | April to June 2020 | Change | | --- | --- | --- | --- | | Revenue | ₹0.35 crore | ₹0.32 crore | +9.4% | | Profit | loss of ₹1.11 crore | loss of ₹1.50 crore | n/a | | Earnings per share | ₹−0.28 | ₹−0.38 | n/a | | Operating margin | −225.7% | −312.5% | +86.8 points | The next results, for July to September 2021, are due by 14 November 2021: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2021). Revenue and profit in ₹ crore.) ## What is the Syncom Healthcare share price history? Syncom Healthcare closed at ₹4.20 on 28 June 2021, up 50.0% from ₹2.80 a year earlier (26 June 2020) and down 50.3% over five years. Its highest weekly close since April 2016 was ₹8.95 on 8 July 2016. ### Syncom Healthcare share price: then and now | When | Close | Change to 28 Jun 2021 | | --- | --- | --- | | 1 week ago · 18 Jun 2021 | ₹4.25 | −1.2% | | 1 month ago · 28 May 2021 | ₹3.50 | +20.0% | | 6 months ago · 1 Jan 2021 | ₹2.65 | +58.5% | | 1 year ago · 26 Jun 2020 | ₹2.80 | +50.0% | | 3 years ago · 29 Jun 2018 | ₹4.40 | −4.5% | | 5 years ago · 1 Jul 2016 | ₹8.45 | −50.3% | | Earliest weekly close in our records · 1 Apr 2016 | ₹6.75 | −37.8% | | Highest weekly close since April 2016 · 8 Jul 2016 | ₹8.95 | −53.1% | | Lowest weekly close since April 2016 · 20 Mar 2020 | ₹0.40 | +950.0% | | 52-week high (weekly close) · 11 Jun 2021 | ₹5.35 | −21.5% | | 52-week low (weekly close) · 9 Oct 2020 | ₹1.15 | +265.2% | Weekly closing prices. Each change is the move from that price to the 28 Jun 2021 close. A day's intraday high or low can go beyond these weekly closes. (275 weekly closes from 1 April 2016 to 28 June 2021.) ## What is the latest news on Syncom Healthcare? Results for April to June 2021: Revenue up 9.4% on a year earlier. 28 Jun 2021: Syncom Healthcare closed at ₹4.20, down 1.2% on the week and up 20.0% on the month. ## What dividend does Syncom Healthcare pay? Syncom Healthcare has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Syncom Healthcare Ltd paid out 0% of its profit as dividends in each of its last 12 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 18 November 2026.) ## What to watch in Syncom Healthcare's next results? When Syncom Healthcare reports July to September 2021, these are the 3 checks that show whether the story is still on course. First: Revenue against the same quarter a year earlier. - Revenue against the same quarter a year earlier. In the Jun 2021 quarter, revenue was +9.4% on a year earlier, and the last four quarters averaged +17.3%. - Whether the operating margin stays near −225.7%. It is 86.8 percentage points higher than four quarters earlier. - Whether debt comes down. Debt is 5.41 times shareholders' equity. ## Which stock lists is Syncom Healthcare on? Syncom Healthcare is not on any of our India lists this week. ## Is Syncom Healthcare profitable? Syncom Healthcare Ltd posted a net loss of ₹1.1 Cr in the Jun 2021 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY23 year was a loss of ₹5.4 Cr. The Jun 2021 quarter's loss is 317.1% of that quarter's revenue. The same quarter a year earlier lost ₹1.5 Cr. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −₹1.1 Cr it is bigger than the quarter's whole revenue of ₹0.3 Cr. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −225.7% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Syncom Healthcare make, and is it growing? Syncom Healthcare Ltd reported ₹0.3 Cr of revenue in the Jun 2021 quarter, +9.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 10 years it has grown −29.1% a year on average. The last full year, FY23, came in at ₹3.0 Cr. The last four reported quarters add to ₹1.9 Cr. FY23 revenue was ₹3.0 Cr, +172.1% on the year before. Recent pace: the last four quarters grew +17.3% on average, against −29.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −69.4%, against −82.2% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Syncom Healthcare keep? Syncom Healthcare Ltd's operating margin was −225.7% in the Jun 2021 quarter, 86.8 percentage points higher than the same quarter a year ago. Across 12 years it has been between −179.8% and 4.0%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed +86.8 percentage points on the year while gross margin changed +124.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Syncom Healthcare's profit turning into cash? Over the last 2 years, 760% of Syncom Healthcare Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY23 its operations used ₹2.1 Cr of cash, against −₹5.4 Cr of profit. After ₹2.0 Cr of estimated spending on assets (worked out from the change in fixed assets plus depreciation; no filed figure), free cash was −₹4.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Syncom Healthcare's cash go? Syncom Healthcare Ltd's customer, stock and supplier day counts are not a useful reading on sales this small (₹3.0 Cr in FY23), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹7.0 Cr on assets over the last 3 years. Averaged over those years that is 77.3% of FY23 revenue a year. Spending on assets: ₹7.0 Cr over the last 3 years, against ₹5.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY23): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Syncom Healthcare's P/E ratio, and how does it compare with its own history? Syncom Healthcare Ltd has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Syncom Healthcare Ltd at 5.6× its FY23 revenue of ₹3.0 Cr. The P/E comes back here once profit turns positive. ## Is the Syncom Healthcare business getting better or worse? Syncom Healthcare Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Syncom Healthcare earn on its capital? Syncom Healthcare Ltd earned a ROCE of −20% in FY23. That is up from a low of −54% in FY21. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −178.5% net margin and 0.11× asset turnover (sales divided by assets). Why the return is what it is (FY23): a −178.5% net margin × 0.11× asset turnover × 7.85× leverage (assets divided by equity) ≈ −154.1% on equity. The margin does its share; borrowing is a big part of it. ## Does Syncom Healthcare have too much debt? Syncom Healthcare Ltd had ₹19.2 Cr of borrowings against ₹3.5 Cr of equity in FY23, so its debt is 5.41× its equity. Its operating profit is −2 times its interest bill. Over 5 years borrowings went from ₹24.9 Cr to ₹19.2 Cr. Over the last 3 of those years it spent ₹7.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Syncom Healthcare shareholding pattern? Promoters cut their stake in Syncom Healthcare Ltd by 24.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 0.1% of the company. Domestic institutions moved +0.0 points over the same period, to 0.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Promoters own under 20%, so this is a widely owned company where institutions, not a family, have the most say. Why the owners changed: promoters drove it (−24.9 points). They reduced their stake. ## How far is Syncom Healthcare from balance-sheet trouble? For Syncom Healthcare Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Syncom Healthcare rank in its industry? 42.4 out of 100, rank 43 of 44 in Pharma - Formulators, with 17% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Syncom Healthcare Ltd scores 42.4 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 43. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 21.2 + 8.7 + 12.5 = 42.4 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Syncom Healthcare compared with? Syncom Healthcare ranks 43 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 42.4 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. Syncom Healthcare Ltd this page SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.2/43.75 · Revenue -69.4% · Profit 63.5% · Operating margin change n/a · 16% evidence Capital efficiency 8.7/31.25 · ROCE -20.2% (year to Mar 2023) · Operating margin -225.7% · 46% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 21.2 + 8.7 + 12.5 = 42.4 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Syncom Healthcare in size? Syncom Healthcare is the 44th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Bafna Pharmaceuticals, Bajaj Healthcare, Lincoln Pharmaceuticals, Kilitch Drugs (India), Zim Laboratories and Influx Healthtech. It is the smallest. ### Pharma - Formulators companies close in size 1. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,112 crore 2. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,078 crore 3. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,031 crore 4. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) ₹804 crore 5. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ₹726 crore 6. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) ₹646 crore 7. Syncom Healthcare Ltd ₹17 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [Kore Digital Ltd](https://www.sectoralpha.in/stocks/kore-digital-ltd) ₹26 crore 2. [ERP Soft Systems Ltd](https://www.sectoralpha.in/stocks/erp-soft-systems-ltd) ₹19 crore · IT - Software 3. Syncom Healthcare Ltd ₹17 crore 4. [Kalyani Commercials Ltd](https://www.sectoralpha.in/stocks/kalyani-commercials-ltd) ₹15 crore 5. [DAPS Advertising Ltd](https://www.sectoralpha.in/stocks/daps-advertising-ltd) ₹11 crore · Entertainment & Media ## What else do people ask about Syncom Healthcare? ### What is Syncom Healthcare's share price? Syncom Healthcare Ltd's share price is ₹4.20, +50.0% over the past year. The whole company is worth ₹16.8 Cr on the market. In the last 52 weeks it traded between ₹1 to ₹5; today it is 73% of the way up from the low, 51.6% above its 200-day average (as of 28 June 2021). ### What were Syncom Healthcare's latest quarterly results? Syncom Healthcare Ltd reported revenue of ₹0.3 Cr and a net loss of ₹1.1 Cr for the Jun 2021 quarter. Earnings per share were −₹0.28. The operating margin was −225.7%, 86.8 percentage points higher than a year earlier (as of 28 June 2021). ### What is Syncom Healthcare's market cap? Syncom Healthcare Ltd's market capitalisation is ₹16.8 Cr at a share price of ₹4.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 28 June 2021). ### How is Syncom Healthcare performing? Syncom Healthcare Ltd's share price has been rising for 28 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 8 weeks running. This describes what the data did, not a rating (as of 28 June 2021). ### Will Syncom Healthcare's share price go up? This page does not forecast Syncom Healthcare Ltd's share price. What it shows instead: the share price is ₹4.20, and it has been rising for 28 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 28 June 2021). ### Who owns Syncom Healthcare? Promoters own 0.1% of Syncom Healthcare Ltd, foreign institutions , domestic institutions 0.0% and the public 99.9% (latest quarter). The biggest change over the last two years: Promoters cut their stake by 24.9 percentage points over 8 quarters (as of 28 June 2021). ### Is Syncom Healthcare's profit real cash? Yes, over the last 2 years, 760% of Syncom Healthcare Ltd's reported profit came in as cash from operations. The latest year was lower at 39%, so the trend is worth watching. In FY23, operating cash was −₹2.1 Cr against reported profit of −₹5.4 Cr. Most of that cash then goes into building new capacity. These are yearly figures (as of 28 June 2021). ### Where is Syncom Healthcare in its business cycle? Syncom Healthcare Ltd's FY23 operating margin was −67.2%, against a 12-year range of −179.8% to 4.0%. The latest quarter was −225.7%, below the bottom of its own yearly range in the latest quarter, a low point in its cycle. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 28 June 2021). ### What could break the Syncom Healthcare story? The main question: promoters moved −24.9 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 28 June 2021). ### Is Syncom Healthcare a stock worth studying right now? What the numbers show: Syncom Healthcare Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 28 June 2021). This is research, not advice. We’re not SEBI-registered.